Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brilaroxazine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Brilaroxazine | DRUG | RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo\[b\]\[1,4\]oxazin-3(4H)-one hydrochloride. |
| Placebo | OTHER | RP5063 matching Placebo |